BACKGROUND: Peroxynitrite plays an important role in the pathogenesis of diabetic complications. Nitrosylated protein expression in peripheral blood monocytes reflects intracellular peroxynitrite injury, and thus could be a marker of higher diagnostic and prognostic value than plasma nitrotyrosine level. The purpose of this pilot study was to assess if peripheral blood monocytes of diabetic subjects accumulate nitrosylated proteins, and if nitrosylated protein expression correlates with blood glucose control, variables of lipid profile, C-reactive protein concentration (a marker of inflammation), and differs in patients with and without diabetic macrovascular and microvascular complications. METHODS: Nitrosylated protein expression in peripheral blood monocytes (Western blot analysis) was assessed in 31 subjects with diabetes mellitus (29 Type 2, 2 Type 1; 20 males, 11 females; mean age 66 years). The presence of microangiopathy was defined by retinopathy, albumin excretion, and/or neuropathy, and macroangiopathy by carotid plaques, a history of myocardial infarction, and/or stroke. RESULTS: Diabetic subjects accumulated significant amounts of nitrosylated proteins in peripheral blood monocytes. Nitrosylated protein expression positively correlated with body weight, blood glucose, HbA (1)C, and plasma C-reactive protein concentrations in the whole cohort as well as in subjects with diabetic macroangiopathy. CONCLUSIONS: Monocyte nitrosylated protein expression is a new biomarker of metabolic control and inflammation in diabetic subjects with macroangiopathy. A more detailed assessment of diabetic microvascular complications in a larger group of patients is needed to determine if this variable can be employed as a biomarker of the presence, severity, and progression of diabetic neuropathy, retinopathy, and nephropathy.
BACKGROUND:Peroxynitrite plays an important role in the pathogenesis of diabetic complications. Nitrosylated protein expression in peripheral blood monocytes reflects intracellular peroxynitriteinjury, and thus could be a marker of higher diagnostic and prognostic value than plasma nitrotyrosine level. The purpose of this pilot study was to assess if peripheral blood monocytes of diabetic subjects accumulate nitrosylated proteins, and if nitrosylated protein expression correlates with blood glucose control, variables of lipid profile, C-reactive protein concentration (a marker of inflammation), and differs in patients with and without diabetic macrovascular and microvascular complications. METHODS: Nitrosylated protein expression in peripheral blood monocytes (Western blot analysis) was assessed in 31 subjects with diabetes mellitus (29 Type 2, 2 Type 1; 20 males, 11 females; mean age 66 years). The presence of microangiopathy was defined by retinopathy, albumin excretion, and/or neuropathy, and macroangiopathy by carotid plaques, a history of myocardial infarction, and/or stroke. RESULTS:Diabetic subjects accumulated significant amounts of nitrosylated proteins in peripheral blood monocytes. Nitrosylated protein expression positively correlated with body weight, blood glucose, HbA (1)C, and plasma C-reactive protein concentrations in the whole cohort as well as in subjects with diabetic macroangiopathy. CONCLUSIONS: Monocyte nitrosylated protein expression is a new biomarker of metabolic control and inflammation in diabetic subjects with macroangiopathy. A more detailed assessment of diabetic microvascular complications in a larger group of patients is needed to determine if this variable can be employed as a biomarker of the presence, severity, and progression of diabetic neuropathy, retinopathy, and nephropathy.
Authors: A Frustaci; J Kajstura; C Chimenti; I Jakoniuk; A Leri; A Maseri; B Nadal-Ginard; P Anversa Journal: Circ Res Date: 2000-12-08 Impact factor: 17.367
Authors: Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan A Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Seth R Bell; John T Groves; Irina G Obrosova Journal: Int J Mol Med Date: 2007-12 Impact factor: 4.101
Authors: Irina G Obrosova; Viktor R Drel; Christine L Oltman; Nazar Mashtalir; Jyoti Tibrewala; John T Groves; Mark A Yorek Journal: Am J Physiol Endocrinol Metab Date: 2007-10-02 Impact factor: 4.310
Authors: Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Jyoti Tibrewala; John T Groves; Irina G Obrosova Journal: Eur J Pharmacol Date: 2007-06-09 Impact factor: 4.432
Authors: Irina G Obrosova; Olga Ilnytska; Valeriy V Lyzogubov; Ivan A Pavlov; Nazar Mashtalir; Jerry L Nadler; Viktor R Drel Journal: Diabetes Date: 2007-07-12 Impact factor: 9.461
Authors: Antonio Ceriello; Cameron W Lush; Tamara Darsow; Ludovica Piconi; Maddelena Corgnali; Nuwan Nanayakkara; Juan P Frias; David Maggs Journal: Diabetes Metab Res Rev Date: 2008-02 Impact factor: 4.876
Authors: M A Ihnat; J E Thorpe; C D Kamat; C Szabó; D E Green; L A Warnke; Z Lacza; A Cselenyák; K Ross; S Shakir; L Piconi; R C Kaltreider; A Ceriello Journal: Diabetologia Date: 2007-05-17 Impact factor: 10.122
Authors: Viktor R Drel; Sergey Lupachyk; Hanna Shevalye; Igor Vareniuk; Weizheng Xu; Jie Zhang; Nicholas A Delamere; Mohammad Shahidullah; Barbara Slusher; Irina G Obrosova Journal: Endocrinology Date: 2010-03-31 Impact factor: 4.736
Authors: Amal Jamil Fatani; Salim Salih Al-Rejaie; Hatem Mustafa Abuohashish; Abdullah Al-Assaf; Mihir Yogeshkumar Parmar; Mohammad Shamsul Ola; Mohammed Mahboobuddin Ahmed Journal: Exp Ther Med Date: 2015-02-20 Impact factor: 2.447
Authors: Xiaozhen Ye; Rong Jiang; Qianqian Zhang; Ruifeng Wang; Cuihua Yang; Jian Ma; Hong Du Journal: J Int Med Res Date: 2016-03-23 Impact factor: 1.671